FDA Approved Treatment for Acute Myeloid Leukemia (AML)

In acute myeloid leukemia (AML) the bone marrow makes excess amounts of a type of white blood cell called myeloblasts. Although AML starts in the bone marrow it quickly progresses to the bloodstream and is hence termed "acute". Other blood-forming cells can also become AML. Symptoms of AML include fever, fatigue and easy bleeding. Vyxeos, a fixed-combination of two chemotherapy drugs Daunorubicin and Cytarabine was approved by the U.S. Food and Drug Administration for the treatment of adults with two types of acute myeloid leukemia (AML).

Related Links